SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091229
Filing Date
2024-08-06
Accepted
2024-08-06 08:40:22
Documents
51
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cogt-20240630.htm   iXBRL 10-Q 1510145
2 EX-31.1 cogt-ex31_1.htm EX-31.1 12931
3 EX-31.2 cogt-ex31_2.htm EX-31.2 12919
4 EX-32.1 cogt-ex32_1.htm EX-32.1 8199
5 EX-32.2 cogt-ex32_2.htm EX-32.2 8174
6 GRAPHIC img158367959_0.jpg GRAPHIC 566283
  Complete submission text file 0000950170-24-091229.txt   7099292

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cogt-20240630.xsd EX-101.SCH 834636
53 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20240630_htm.xml XML 905816
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38443 | Film No.: 241177242
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)